FindTrial
Sign In

cemiplimab (maintenance)

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals, Intergroupe Francophone de Cancerologie Thoracique

Conditions

Diffuse Intrinsic Pontine GliomaHigh Grade GliomaRefractory Central Nervous System TumorRefractory Solid TumorRelapsed Central Nervous System TumorRelapsed Solid TumorStage III NSCLC

Phase 1

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
TerminatedNCT03690869
Regeneron PharmaceuticalsDiffuse Intrinsic Pontine Glioma, High Grade Glioma, Refractory Central Nervous System Tumor +3
Start: 2018-09-24End: 2023-05-10Updated: 2025-04-08

Phase 2

Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
RecruitingNCT06656598
Intergroupe Francophone de Cancerologie ThoraciqueStage III NSCLC
Start: 2025-11-07End: 2032-01-01Target: 152Updated: 2026-08-11

Related Papers

Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Frontiers in Oncology2021-06-0811 citations
RBTT-09. A PHASE 1 STUDY OF CEMIPLIMAB IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) SOLID AND CENTRAL NERVOUS SYSTEM (CNS) TUMORS
Neuro-Oncology2019-11-01